GLP-1RAs Show No Significant Motor Benefit in Parkinson's Disease Meta-Analysis
Photo by Navy Medicine / Unsplash
Key Takeaway
Interpret GLP-1RA efficacy for PD motor symptoms cautiously given no significant benefit in meta-analysis.
This systematic review and meta-analysis evaluated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with Parkinson's disease. The analysis pooled data from 5 randomized controlled trials involving 708 participants, comparing GLP-1RAs to placebo. The primary outcome was change in motor examination scores measured by the MDS-UPDRS Part III scale.
The analysis found no statistically significant benefit of GLP-1RAs on motor scores. For patients off medication, the mean difference was -2.00 points (95% CI: -4.12 to 0.11, p = 0.06). For patients on medication, the mean difference was -1.40 points (95% CI: -3.42 to 0.62, p = 0.17). Secondary outcomes including other MDS-UPDRS parts, PDQ-39, and NMSS also showed no significant benefits.
Regarding safety, GLP-1RAs were associated with increased gastrointestinal side effects compared to placebo. The relative risks were: nausea 2.09, vomiting 4.53, constipation 1.60, and weight loss 1.83. Information on serious adverse events, discontinuation rates, and tolerability was not reported in the meta-analysis.
Key limitations include that follow-up duration was not reported, and the confidence intervals for primary outcomes crossed zero, indicating uncertainty about potential benefit or harm. The evidence represents an association rather than demonstrating causation. These findings suggest that current evidence does not support GLP-1RAs as effective treatments for motor symptoms in Parkinson's disease, though they confirm the expected gastrointestinal side effect profile.
More on Parkinson's Disease
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
New drugs help people with severe mental illness lose weight safely
This systematic review and meta-analysis evaluated glucagon-like peptide-1 receptor agonists in individuals with severe mental illness who h…
New weight loss drugs work well and stay safe for people with severe mental illness who struggle with obesity and high blood sugar.
Meta-analysis shows MRI volumetric differences in Parkinson's disease with mild cognitive impairment versus cognitively normal patients
New scan signs reveal early brain changes in Parkinson's dementia risk
This systematic review and meta-analysis evaluates gray matter volume alterations across six subcortical regions in patients with Parkinson'…
A new scan pattern shows specific brain shrinkage in Parkinson's patients who are starting to forget things, helping doctors catch dementia …
Review of LLM-generated synthetic Parkinson's patients for in silico trials
AI creates synthetic patients to help Parkinson's trials work better
This review synthesizes a methodological proof-of-concept on generating synthetic Parkinson's disease patients using a large language model.…
New AI technology creates virtual patients to help test Parkinson's drugs without breaking privacy rules during clinical research.
View Original Abstract ↓
BACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disorder with no currently approved disease-modifying treatments. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally used in type 2 diabetes, have demonstrated neuroprotective and anti-inflammatory effects in preclinical PD models. This systematic review and meta-analysis evaluated the efficacy and safety of GLP-1RAs in patients with PD.
METHODS: A systematic search of MEDLINE, Embase, Cochrane CENTRAL, and ClinicalTrials.gov was conducted through July 2025 for randomized controlled trials (RCTs) comparing GLP-1RAs to placebo in PD. Primary outcomes included MDS-UPDRS Part III (motor examination) both on and off medication. Secondary outcomes included MDS-UPDRS Parts I, II, IV, PDQ-39, NMSS, and adverse effects. Data were pooled using a random-effects model with results reported as mean differences (MD) or risk ratios (RR) with 95% confidence intervals (CI).
RESULTS: Five RCTs involving 708 participants were included. No statistically significant differences were found in MDS-UPDRS Part III scores off medication (MD: -2.00, 95% CI: -4.12 to 0.11, p = 0.06) or on medication (MD: -1.40, 95% CI: -3.42 to 0.62, p = 0.17). Secondary outcomes also showed no significant benefits with GLP-1RA use. However, GLP-1RAs were associated with increased gastrointestinal side effects, including nausea (RR: 2.09), vomiting (RR: 4.53), constipation (RR: 1.60), and weight loss (RR: 1.83).
CONCLUSION: Current evidence does not demonstrate a statistically significant overall benefit of GLP-1RAs on efficacy outcomes in PD, while gastrointestinal adverse events are increased. More trials are needed to clarify their disease-modifying potential.
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke.
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
Related in Neurology
Neck muscle vibration improves neglect symptoms in right-hemispheric stroke patients
Vibrating neck muscles help stroke patients ignore the empty side of their vision
This randomized clinical trial enrolled 20 patients with right-hemispheric stroke and unilateral spatial neglect. The active neck muscle vib…
A small trial found that vibrating neck muscles helped stroke patients improve their ability to see on the side they missed.
Aerobic and strength training reduce fatigue in multiple sclerosis patients
Aerobic or strength training eases MS fatigue, trial finds
This randomized effectiveness trial in 62 persons with multiple sclerosis and fatigue found that 8 weeks of aerobic training, strength train…
A small trial finds that aerobic and strength training each reduce fatigue in MS, with no clear winner among exercise types.
Modified CIMT with trunk restraint improves function in chronic stroke patients
Six weeks of tailored therapy improved function and quality of life for chronic stroke patients.
A single-blinded RCT in 34 chronic stroke patients found that adding patient-tailored modified constraint-induced movement therapy (mCIMT) w…
Thirty-four people with long-term stroke saw better movement and balance after six weeks of a specific therapy mix compared to standard care…
Laughter yoga reduced fatigue in people with multiple sclerosis in a randomized controlled trial
Laughter Yoga Cuts Fatigue And Improves Sleep For Multiple Sclerosis Patients
This randomized controlled trial enrolled 42 people with multiple sclerosis. Participants in the intervention group received 12 sessions of …
People with multiple sclerosis who practiced laughter yoga reported less tiredness and better sleep after just twelve sessions.
From Other Specialties
Systematic review and meta-analysis shows immune checkpoint inhibitors improve survival in first-line ES-SCLC but not as single agents in second-line
Immune drugs boost survival in small-cell lung cancer
This systematic review and meta-analysis evaluates immune checkpoint inhibitors combined with chemotherapy versus chemotherapy alone for ext…
Adding immune checkpoint inhibitors to chemotherapy helps patients with extensive-stage small-cell lung cancer live longer.
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
Lung Ultrasound Shows Good Diagnostic Accuracy for ARDS in Meta-Analysis of 5888 Patients
Lung ultrasound shows high accuracy for detecting severe breathing trouble in ICU patients
This systematic review and meta-analysis of 5888 patients found that lung ultrasound (LUS) has good diagnostic accuracy for acute respirator…
A large review of 5,888 patients found lung ultrasound is a highly accurate, safe way to check for severe lung injury without using radiatio…
Kidney-directed SBRT shows modest renal function decline in inoperable patients
Small study shows kidney function drops after radiation for hard-to-treat tumors
This prospective phase 2 single-arm trial evaluated kidney-directed SBRT in 30 patients with primary or metastatic renal tumors who were med…
Radiation to treat kidney tumors may lower kidney function over two years, even when surgery is not an option.